Global Microbiome Market Report, Trends, Share, Outlook, and Forecast to 2028

Microbiome Market Overview

The global microbiome market was valued at USD 1.7 billion in 2021, and it is estimated to reach USD 2.2 billion in 2028 with a CAGR of 7.2% during the forecast period of 2022-2028. Growing gastrointestinal disorders, technological advancements, rising investments in microbiome projects in developing countries, and the lucrative company of market players across the globe are elements responsible for the rapid expansion of the global microbiome market. The growing attention to women’s health drives the global human microbiome market. Market stakeholders expand their services arms by developing innovative and technologically progressive products to gain revenue benefits.

What is Microbiome?

The microbiome is a genetic element of different microorganisms such as bacteria, fungi, protozoa, and viruses present inside and on the human body. The microbiome consists of microbes that are both useful and potentially dangerous. Most are symbiotic, and some are pathogenic (promoting disease) in smaller numbers. In a healthy body, pathogenic and symbiotic microbiota coexist without issues. But dysbiosis occurs if a balance is disrupted—brought on by infectious illnesses, certain diets, or the prolonged use of antibiotics or other bacteria-destroying medications—stopping these normal interactions. As a result, the body may become more susceptible to disease.

Growth Drivers

Increasing Prevalence of Gastrointestinal and Metabolic Conditions Push Microbiome Market

The growth of the global microbiome market can be attributed to the increasing prevalence of gastrointestinal & metabolic disorders. The rising awareness about the severity of chronic diseases such as cancer-driving expands the global microbiome market. Major market performers in the microbiome diagnostics segment are launching innovative products to cure several common gut problems, including Crohn’s disease and ulcerative colitis. The segment’s growth can be characterized by the high number of microbiome diagnostic companies and the ease of non-invasive testing delivered by this method.

Growth in Industry-Institute Partnerships and High Unmet Medical Needs to Drive Global Market

Many microbiome therapeutics and diagnostics are targeted toward a market with enormous unmet medical requirements. For example, the current standard of care for Clostridium difficile infection (CDI) is a treatment with antibiotics. Antibiotic treatment can determine acute infection; regardless, it also has the possibility of worsening dysbiosis in patients. It makes them potentially more sensitive to the recurrence of CDI. Patients with recurrent CDI accept many rounds of antibiotics that could worsen dysbiosis and are more likely to face a relapse. Key players strive to resolve unmet medical conditions for cancer, CNS disorders, women’s health disorders, skin disorders, and rare diseases through their microbiome-based products.

Opportunities

Advances in Research & Development Activities in Microbiome Market Create Lucrative Opportunities

The microbiome is a genetic component of microorganisms such as bacteria, fungi, protozoa, and viruses, which live inside and on the human body. Manufacturers operating in the global microbiome market are developing diagnostic and therapeutic products. The increasing research & development activities in the microbiome market contribute to the growth of the global microbiome market. Technological improvements in metagenomics and next-generation sequencing have made microbiome-based testing simple and cost-effective, paving the way to rapidly examining the genomic content of microorganisms from human samples. It has supported the development process for microbiome-based diagnostics. Gastrointestinal and metabolic conditions are likely to capture the leading share of the diagnostics market due to the advancement in the focus of companies toward developing a comfortable research platform for gut health-based diseases, such as irritable bowel syndrome and Crohn’s condition. Rising actions by manufacturers to create non-invasive tests create potential opportunities for market growth.

Restraints

Obstacles to proving the causal connection between dysbiosis and diseases

The human body is home to various communities of symbiotic, commensal, and pathogenic microorganisms, collectively understood as the microbiota. Different studies also indicated that only 30-40 species share the bulk of microbiota among people. Researching specific bacteria from among trillions of species can be highly problematic. High-throughput omics technologies can determine the identical bacterial species involved and understand how homeostasis between humans and microbes is supported. According to microbiome research, microbiome dysbiosis results in multiple chronic and lifestyle diseases, such as obesity, diabetes, and various digestive disorders. The current methods for determining microbial markers for diagnostic objectives depend on comparisons with similar control groups of healthy individuals. Choosing the correct microbial chassis for a microbiota-based therapeutic is challenging as indicating which microbe is best suited for any application.

Pre Covid-19 Impact on Global Microbiome Market

Before the covid-19 period, many human medical conditions, such as inflammatory bowel diseases and obesity, were closely connected with the composition of the gut microbial community; also, conditions such as asthma and diabetes are thought to be impacting this microbial community. Many measures are being taken to alter the gut microbiome to eradicate different diseases. Probiotics, prebiotics, dietary supplements, and foods that include live microbes have been studied thoroughly to assess their effects on human health, increasing the microbiome market’s growth.

Covid-19 Impact on Global Microbiome Market

During the Covid-19 period, the pandemic has created massive disruptions to clinical trial research worldwide. As in other parts of life, the virus has severely impacted the ability to conduct trials in safe and effective ways. It is especially true when considering that trials often deal with vulnerable populations most at threat from exposure to covid-19. Seres Therapeutics’ SER-287 development action was adversely impacted by the pandemic and multiple clinical sites halting non-essential procedures, including endoscopies. Similarly, covid-19 has adversely affected and could continue to impact other companies’ businesses, including their preclinical investigations and clinical trials of microbiome-based therapeutics and diagnostic products.

Post Covid-19 Impact on Global Microbiome Market

After the covid-19 period, this technical and expertise-oriented industry research report scrutinizes the Microbiome therapeutics industry’s technical and commercial business outlook. The report analyzes and declares the historical and current trends analysis of the microbiome therapeutics industry and subsequently recommends the projected trends observed in the microbiome therapeutics market during the upcoming years. Other key factors pushing the growth of this market are the increasing burden of lifestyle-related diseases and the growing senior population. Lowering the level of microbiota will increase the growth of fatal infectious diseases and organisms.

By Application Segmental Analysis

Based on the application segment, the global microbiome market is segmented into Therapeutics and Diagnostics. The therapeutics segment holds the largest share of the microbiome market. The upsurge in funding for R&D into microbiome-based therapies worldwide is the primary aspect pushing the growth of this application segment. In addition, technological improvements, the increasing number of clinical trials for the diagnostics segment, and expanding partnerships between key market participants and research institutes also help market growth.

By Disease Type Segmental Analysis

Based on Disease Type, the global microbiome market is segmented into Obesity, Diabetes, Autoimmune Disorder, Metabolic, Gastrointestinal Disorders, Cancer and other diseases. The infectious disease segment is anticipated to register the highest growth rate during the forecast period. Increasing cognizance of the ill outcomes of antibiotic use on the natural flora (such as disruptions) has highlighted the demand for specific bacterial-targeted therapy for infectious diseases. The rising incidence of infections due to microbial dysbiosis due to antibiotic treatment and the increasing number of clinical practices for developing target-specific microbiome-based therapies are the major factors driving the growth of this segment.

By Regional Segmental Analysis

Based on region, the global microbiome market is segmented into North America, Europe, Asia-Pacific, South America and The Middle East & Africa. North America calculated for the largest share of the overall market, followed by Europe. The increasing incidences of lifestyle conditions, rising attention to preventative healthcare, availability of budget for microbiome research, and the growing number of microbiome research & clinical activities are pushing the market’s growth in North America.

Competitors Analysis

The companies include Microbiotica, Rebiotix, Inc., Locus Biosciences, Second Genome, Kallyope, Finch Therapeutics, Concentric, AOBiome, Enterome, Metabiomics Corporate and other prominent players in the global microbiome market. Key Stakeholders

• Market research and consulting firms
• Industry associations
• Global Microbiome Manufacturing Firms
• Local Governments
• Regulatory bodies
• Suppliers
• Retailers

Recent Developments

• In 2022- OptiBiotix Health Plc. Contracted an exclusive sales and distribution agreement with Nahdi Medical Co., GoFigure, and SlimBiome Medical weight management products will be unrestricted in the KSA from early 2022 through the new agreement with Nahdi.
• In 2020-4D, pharma connected with Longevity Acquisition Corporation to gain a NASDAQ listing. In turn, Longevity will help and accelerate the ongoing development of 4D pharma’s Live Biotherapeutic. Live Biotherapeutics is a novel and occurring class of drugs described by the FDA as biological products that include a live organism, such as a bacterium, that applies to the deterrence, treatment, or treatment of a disease.
• In 2019- Series collaborated with AstraZeneca to better understand the microbiome in increasing cancer immunotherapy effectiveness and potential synergy with AstraZeneca compounds.

Scope of the Report

Report Attribute	Details
Revenue in 2021	USD 1.7 billion
The revenue forecast in 2028	USD 2.2 billion
Growth rate	CAGR of 7.2% from 2022 to 2028.
Historical data	2017 – 2020
Base Year	2021
Forecast period	2022 – 2028
Region covered	North America, Europe, Asia-Pacific, South America, and Middle East & Africa
Key companies Profiled	The companies Microbiotica, Rebiotix, Inc., Locus Biosciences, Second Genome, Kallyope, Finch Therapeutics, Concentric, AOBiome, Enterome and Metabiomics Corporate are the key players.

Market Modelling

By-Products

• Probiotics
• Prebiotics
• Medical Foods
• Supplements
• Others

By Application

• Therapeutics
• Diagnostics

By Disease Type

• Obesity
• Diabetes
• Autoimmune Disorder
• Metabolic
• Gastrointestinal Disorders
• Cancer
• Other Disease

By Region

• North America
• Europe
• Asia Pacific
• South America
• The Middle East & Africa